|
|
|
| Research progress of platelet-rich plasma in orthopaedics based on CiteSpace analysis |
| DU Jiazhe1, XU Xilin2, LIU Bo1, LI Lulu1, ZHANG Xianda1, DONG Bochang1, KANG Boyuan1, ZHANG Xiaofeng2, 3 |
| 1.Graduate School, Heilongjiang University of Chinese Medicine, Harbin 150040, China; 2.Orthopaedic Department III, the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin 150001, China; 3.Heilongjiang Traditional Chinese Medicine Administration, Harbin 150001, China |
|
| Cite this article: |
|
DU Jiazhe,XU Xilin,LIU Bo, et al. Research progress of platelet-rich plasma in orthopaedics based on CiteSpace analysis[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2023, 53(8): 677-683.
|
|
|
|
Abstract Objective: To map and analyze, on the basis of CiteSpace software, the use of platelet-rich plasma in the field of orthopedics at home and abroad, and to summarize its research progress and predict the development trend in this field. Methods: Using CNKI, VIP, Wanfang, PubMed and Web of Science databases as data sources, the relevant literature on platelet-rich plasma in the field of orthopedics from the date of database construction to November 1, 2022 was screened, visualized and analyzed by CiteSpace software and discussed in terms of annual publication volume, authors and keywords. Results: A collection of 1 089 papers related to platelet-rich plasma and orthopedics (core journals) from three major domestic databases were screened, and 2 568 and 1 645 papers were obtained from PubMed database and Web of Science core collection, respectively. The results suggested that the number of domestic and international publications had been increasing year by year, with the research focus mainly on osteoarthritis, bone tissue engineering, tendinopathy, and bone defects. Conclusion: The further application of platelet-rich plasma in the future should focus on the direction of “discussion on the biological molecular mechanism of treatment of diseases”, “establishment of injection norms and standards”, “improvement of clinical efficacy of osteoarthritis” and “combination with bone tissue engineering”.
|
|
|
| |
|
|
|
|
|
|
